Literature DB >> 18629924

CHO DUKX cell lineages preadapted to growth in serum-free suspension culture enable rapid development of cell culture processes for the manufacture of recombinant proteins.

M S Sinacore1, T S Charlebois, S Harrison, S Brennan, T Richards, M Hamilton, S Scott, S Brodeur, P Oakes, M Leonard, M Switzer, A Anagnostopoulos, B Foster, A Harris, M Jankowski, M Bond, S Martin, S R Adamson.   

Abstract

Using an adaptive strategy, Chinese hamster ovary (CHO) cell lines were developed that are capable of robust growth in serum-free suspension culture. These preadapted derivatives of the commonly used strain of CHO cells (CHO DUKX), termed PA-DUKX, were used for the introduction and stable expression of several heterologous human genes. A significant advantage of recombinant PA-DUKX cells was their ability to readily resume growth in serum-free suspension culture after transfection and amplification of heterologous genes. Expression of recombinant human proteins in PA-DUKX cells was quantitatively similar to that of lineages generated using conventional CHO DUKX cells. In addition, recombinant human proteins expressed by transfected PA-DUKX lineages were shown to be biochemically and structurally similar to those expressed in CHO DUKX cells, PA-DUKX host cell technology provides an opportunity for reducing the time and resources required to develop large-scale, suspension culture-based manufacturing processes employing serum-free medium. (c) 1996 John Wiley & Sons, Inc.

Entities:  

Year:  1996        PMID: 18629924     DOI: 10.1002/(SICI)1097-0290(19961120)52:4<518::AID-BIT7>3.0.CO;2-S

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  9 in total

1.  Adaptation of mammalian cells to growth in serum-free media.

Authors:  M S Sinacore; D Drapeau; S R Adamson
Journal:  Mol Biotechnol       Date:  2000-07       Impact factor: 2.695

2.  Proteomic profiling of recombinant cells from large-scale mammalian cell culture processes.

Authors:  Paula Meleady
Journal:  Cytotechnology       Date:  2007-02-24       Impact factor: 2.058

3.  Stable expression of recombinant human coagulation factor XIII in protein-free suspension culture of Chinese hamster ovary cells.

Authors:  B H Chun; W G Bang; Y K Park; S K Woo
Journal:  Cytotechnology       Date:  2001-11       Impact factor: 2.058

4.  Isolation, characterization and recombinant protein expression in Veggie-CHO: A serum-free CHO host cell line.

Authors:  B Rasmussen; R Davis; J Thomas; P Reddy
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

5.  Heparin promotes suspension adaptation process of CHO-TS28 cells by eliminating cell aggregation.

Authors:  Ling Li; Jun Qin; Qiang Feng; Hao Tang; Rong Liu; Liqing Xu; Zhinan Chen
Journal:  Mol Biotechnol       Date:  2011-01       Impact factor: 2.695

6.  Development of a serum-free medium for dihydrofolate reductase-deficient Chinese hamster ovary cells (DG44) using a statistical design: beneficial effect of weaning of cells.

Authors:  E J Kim; N S Kim; G M Lee
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-04       Impact factor: 2.416

7.  The effects of culture conditions on the glycosylation of secreted human placental alkaline phosphatase produced in Chinese hamster ovary cells.

Authors:  Jong Hyun Nam; Fuming Zhang; Myriam Ermonval; Robert J Linhardt; Susan T Sharfstein
Journal:  Biotechnol Bioeng       Date:  2008-08-15       Impact factor: 4.530

8.  Developement of serum-free media in CHO-DG44 cells using a central composite statistical design.

Authors:  Ananth Parampalli; Kent Eskridge; Leonard Smith; Michael M Meagher; Mark C Mowry; Anuradha Subramanian
Journal:  Cytotechnology       Date:  2007-06-05       Impact factor: 2.058

9.  The relationship between mTOR signalling pathway and recombinant antibody productivity in CHO cell lines.

Authors:  Raihana Edros; Susan McDonnell; Mohamed Al-Rubeai
Journal:  BMC Biotechnol       Date:  2014-02-17       Impact factor: 2.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.